HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Saturday.
Several other research analysts have also recently issued reports on HTGM. Canaccord Genuity raised their target price on shares of HTG Molecular Diagnostics from $5.50 to $6.50 and gave the stock a “hold” rating in a report on Wednesday, April 19th. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a report on Thursday, May 11th. Rodman & Renshaw raised their target price on shares of HTG Molecular Diagnostics from $4.50 to $6.00 and gave the stock a “buy” rating in a report on Tuesday, May 16th. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of HTG Molecular Diagnostics in a report on Thursday, June 29th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $5.75.
Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) opened at 2.22 on Friday. HTG Molecular Diagnostics has a 12 month low of $1.20 and a 12 month high of $13.25. The stock’s 50 day moving average is $2.43 and its 200-day moving average is $3.36. The company’s market cap is $21.69 million.
HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its earnings results on Tuesday, August 8th. The medical research company reported ($0.60) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.60). HTG Molecular Diagnostics had a negative net margin of 432.74% and a negative return on equity of 1,538.49%. The firm had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $1.80 million. On average, equities analysts forecast that HTG Molecular Diagnostics will post ($2.25) EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in HTGM. UBS Group AG purchased a new stake in HTG Molecular Diagnostics during the first quarter valued at approximately $137,000. Two Sigma Securities LLC purchased a new stake in HTG Molecular Diagnostics during the first quarter valued at approximately $150,000. Granahan Investment Management Inc. MA purchased a new stake in HTG Molecular Diagnostics during the first quarter valued at approximately $228,000. Renaissance Technologies LLC raised its stake in HTG Molecular Diagnostics by 32.3% in the fourth quarter. Renaissance Technologies LLC now owns 58,200 shares of the medical research company’s stock valued at $130,000 after buying an additional 14,206 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in HTG Molecular Diagnostics by 38.9% in the second quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock valued at $359,000 after buying an additional 37,841 shares in the last quarter. Institutional investors own 28.05% of the company’s stock.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about HTG Molecular Diagnostics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for HTG Molecular Diagnostics Inc. and related companies.